Nakamura M, Yamaguchi T
Third Department of Internal Medicine, Toho University, Ohashi Hospital.
Nihon Rinsho. 1993 May;51(5):1322-7.
Development of heart failure complicating acute myocardial infarction is directly related to the extent of myocardial infarction and complex architectural changes defined as infarct expansion and remodeling. ACE inhibitors are an exciting class of agents that have the potentiality to prevent left ventricular dilatation, evolution of heart failure and death in the acute myocardial infarction setting. Besides, reperfusion is a important intervention that prevents infarct expansion in the early period after myocardial infarction. Early reperfusion limits expansion by infarct size reduction while late reperfusion reduces expansion independent of myocardial salvage by limiting transmural damage and improving the infarct healing. Therefore, reperfusion therapy decreases the incidence of congestive heart failure and significantly improves the prognosis of heart failure. On the other hand, the in-hospital mortality rate of cardiogenic shock, resulting from acute myocardial infarction, remains high, although primary PTCA has apparently resulted in substantial improvement in mortality of myocardial infarction shock. Thus, reperfusion treatment may be more effective in preventing rather than treating cardiogenic shock.
急性心肌梗死并发心力衰竭的发生与心肌梗死范围以及定义为梗死扩展和重塑的复杂结构变化直接相关。血管紧张素转换酶抑制剂是一类令人兴奋的药物,它们有可能在急性心肌梗死情况下预防左心室扩张、心力衰竭的进展和死亡。此外,再灌注是一种重要的干预措施,可在心肌梗死后早期预防梗死扩展。早期再灌注通过缩小梗死面积来限制扩展,而晚期再灌注通过限制透壁损伤和改善梗死愈合来减少扩展,与心肌挽救无关。因此,再灌注治疗可降低充血性心力衰竭的发生率,并显著改善心力衰竭的预后。另一方面,尽管直接经皮冠状动脉腔内血管成形术(PTCA)显然已使心肌梗死性休克的死亡率有了实质性改善,但急性心肌梗死所致心源性休克的院内死亡率仍然很高。因此,再灌注治疗在预防而非治疗心源性休克方面可能更有效。